{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:53:45Z","timestamp":1785412425181,"version":"3.56.0"},"reference-count":93,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008207","name":"AstraZeneca Canada","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008207","id-type":"DOI","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/04n8fbz89","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>First-line (1L) therapy for mantle cell lymphoma (MCL) continues to evolve rapidly, with several recent phase II and phase III trials consistently showing the activity of novel covalent Bruton\u2019s tyrosine kinase inhibitor (cBTKi) combinations. Historical treatment selection criteria such as patient age, fitness, and eligibility for autologous stem cell transplantation generally remain applicable for some, but not all, of these novel regimens. This potential for flexibility necessitates the consideration of additional factors during decision-making, such as MCL biology, patient risk tolerance, logistical and resource implications, and the impact on use of later-line options. This paper presents three illustrative patient cases to explore 1L therapy selection among these new and emerging cBTKi options. The realized and anticipated benefits, limitations, and challenges and persisting evidence gaps associated with these regimens are discussed.<\/jats:p>","DOI":"10.3390\/curroncol33070426","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T09:00:52Z","timestamp":1784278852000},"page":"426","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["First-Line Bruton\u2019s Tyrosine Kinase Inhibitor-Based Regimens for Mantle Cell Lymphoma"],"prefix":"10.3390","volume":"33","author":[{"given":"Robert","family":"Puckrin","sequence":"first","affiliation":[{"name":"Arthur J.E. Child Comprehensive Cancer Centre, University of Calgary, Calgary, AB T2N 5G2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4625-3009","authenticated-orcid":false,"given":"Diego","family":"Villa","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC V5Z 1L3, Canada"},{"name":"Division of Medical Oncology, Department of Medicine, University of British Columbia, Vancouver, BC V5Z 4E6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Fleury","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire de Qu\u00e9bec, Universit\u00e9 Laval, Qu\u00e9bec City, QC G1J 5B3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Larouche","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire de Qu\u00e9bec, Universit\u00e9 Laval, Qu\u00e9bec City, QC G1J 5B3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6117-320X","authenticated-orcid":false,"given":"John","family":"Kuruvilla","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMra2202672","article-title":"Mantle-cell lymphoma","volume":"386","author":"Armitage","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e70073","DOI":"10.1002\/hon.70073","article-title":"First line therapy in mantle cell lymphoma\u2014The role of BTKi in the initial treatment of transplant-eligible and -ineligible patients","volume":"43","author":"Silkenstedt","year":"2025","journal-title":"Hematol. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: Lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of mature lymphoid neoplasms: A report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): Prolonged remissions without survival plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41408-019-0209-5","article-title":"Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: Progressive shortening in response duration and survival after each relapse","volume":"9","author":"Kumar","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1200\/JCO.22.01780","article-title":"High-dose cytarabine and autologous stem-cell transplantation in mantle cell lymphoma: Long-term follow-up of the randomized Mantle Cell Lymphoma Younger trial of the European Mantle Cell Lymphoma Network","volume":"41","author":"Hermine","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e648","DOI":"10.1016\/S2352-3026(21)00195-2","article-title":"Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: A post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial","volume":"8","author":"Zoellner","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Hoster","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/bjh.20239","article-title":"Therapeutic advances and gradual improvement in overall survival in mantle cell lymphoma over four decades","volume":"207","author":"Alzahrani","year":"2025","journal-title":"Br. J. Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","article-title":"Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: Results of a prospective randomized trial of the European MCL Network","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): A single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: Updated safety and efficacy results","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1182\/bloodadvances.2020004074","article-title":"Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma","volume":"5","author":"Tam","year":"2021","journal-title":"Blood Adv."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","article-title":"Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): A three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network","volume":"403","author":"Dreyling","year":"2024","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","article-title":"Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma","volume":"386","author":"Wang","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1200\/JCO-25-00690","article-title":"Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma","volume":"43","author":"Wang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/S0140-6736(25)01432-1","article-title":"Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): A randomised, open-label, phase 2\/3 superiority trial","volume":"406","author":"Lewis","year":"2025","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1200\/JCO-25-00146","article-title":"Mantle cell lymphoma: Optimal treatment with Bruton tyrosine kinase-targeted approaches","volume":"43","author":"Eyre","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_20","first-page":"5","article-title":"Mantle cell lymphoma: Evolving frontline treatment strategies","volume":"3","author":"Gong","year":"2024","journal-title":"Can. Hematol. Today"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1182\/blood.2023022352","article-title":"Frontline management of mantle cell lymphoma","volume":"145","author":"Ryan","year":"2025","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1182\/blood.2023022354","article-title":"High\u2013risk MCL: Recognition and treatment","volume":"145","author":"Jain","year":"2025","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/hematology.2024000658","article-title":"Your chemo is no good here: Management of high-risk MCL","volume":"2024","author":"Sawalha","year":"2024","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40256-025-00757-6","article-title":"Cardiovascular safety of Bruton tyrosine kinase inhibitors: From ibrutinib to next-generation agents","volume":"26","author":"Spadafora","year":"2026","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e712","DOI":"10.1097\/HS9.0000000000000712","article-title":"Long-term outcomes with ibrutinib treatment for patients with relapsed\/refractory mantle cell lymphoma: A pooled analysis of 3 clinical trials with nearly 10 years of follow-up","volume":"6","author":"Dreyling","year":"2022","journal-title":"Hemasphere"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/S0140-6736(26)00362-4","article-title":"Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18\u201365 years with mantle cell lymphoma (TRIANGLE): 4.5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network","volume":"407","author":"Dreyling","year":"2026","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1182\/blood-2024-200290","article-title":"High-risk subgroups and MRD: An updated analysis of the phase 3 ECHO trial of acalabrutinib with bendamustine\/rituximab in previously untreated mantle cell lymphoma","volume":"144","author":"Dreyling","year":"2024","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2025-885","article-title":"Time to third-line treatment after bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: Updated analysis of the phase 3 ECHO trial after 50 months of follow-up","volume":"146","author":"Wang","year":"2025","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1182\/blood-2023-179375","article-title":"Rituximab combined with chemotherapy and acalabrutinib prior to autologous stem cell transplantation in mantle cell lymphoma: The Rectangle trial","volume":"142","author":"Villa","year":"2023","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1182\/blood-2024-192939","article-title":"Acalabrutinib and rituximab in elderly patients with newly diagnosed mantle cell lymphoma including a matched population-based external comparator- the Nordic Lymphoma Group NLG-MCL8 (ALTAMIRA) phase II trial (oral presentation)","volume":"144","author":"Jerkeman","year":"2024","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood.2024025563","article-title":"Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation","volume":"145","author":"Kumar","year":"2025","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1182\/blood-2025-884","article-title":"Acalabrutinib plus venetoclax and rituximab in patients with treatment-naive (TN) mantle cell lymphoma (MCL): Results from the phase 2 TrAVeRse study","volume":"146","author":"Hawkes","year":"2025","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.1200\/JCO.2025.43.16_suppl.7017","article-title":"Efficacy and safety of first-line ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) who were older or had TP53 mutations in the SYMPATICO study","volume":"43","author":"Wang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"100184","DOI":"10.1016\/j.bneo.2025.100184","article-title":"Outcomes of transplant-eligible and transplant-ineligible patients with mantle cell lymphoma in Ontario","volume":"3","author":"Suleman","year":"2026","journal-title":"Blood Neoplasia"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1038\/s41409-020-01198-2","article-title":"Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides longer disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: Results from the LyMA prospective trial","volume":"56","author":"Tessoulin","year":"2021","journal-title":"Bone Marrow Transpl."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Feng, G., Zhou, X., Chen, J., Li, D., and Chen, L. (2023). Platinum drugs-related safety profile: The latest five-year analysis from FDA adverse event reporting system data. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1012093"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/hon.2328","article-title":"Comparative toxicities of 3 platinum-containing chemotherapy regimens in relapsed\/refractory lymphoma patients","volume":"35","author":"Tixier","year":"2017","journal-title":"Hematol. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1182\/bloodadvances.2024014309","article-title":"Back from (BTKi) holiday","volume":"9","author":"Brander","year":"2025","journal-title":"Blood Adv."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: Primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/1078-0432.CCR-22-3934","article-title":"Absence of BTK, BCL2, and PLCG2 mutations in chronic lymphocytic leukemia relapsing after first-line treatment with fixed-duration ibrutinib plus venetoclax","volume":"30","author":"Jain","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1158\/1078-0432.CCR-23-2872","article-title":"Overcoming resistance in chronic lymphocytic leukemia-maybe less is more?","volume":"30","author":"Davids","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Lemieux, C., Phua, C.W., Robinson, K.S., Owen, C., and Banerji, V. (2025). Contemporary fixed-duration treatment options in the first-line setting of chronic lymphocytic leukemia: Perspectives from a publicly funded healthcare system. Curr. Oncol., 32.","DOI":"10.3390\/curroncol32100543"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2147\/PPA.S510401","article-title":"Preferences for first-line chronic lymphocytic leukemia treatments: Results from a multinational study on the perspectives of patients and physicians","volume":"19","author":"Sile","year":"2025","journal-title":"Patient Prefer. Adherence"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1182\/blood.2020008758","article-title":"Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines","volume":"137","author":"Pleyer","year":"2021","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1038\/s41375-021-01270-w","article-title":"COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia","volume":"35","author":"Roeker","year":"2021","journal-title":"Leukemia"},{"key":"ref_48","unstructured":"Kite Pharma (2025). Product monograph. TECARTUS (Brexucabtagene Autoleucel), Gilead Sciences Canada, Inc.. Available online: https:\/\/www.gilead.com\/en-ca\/-\/media\/gilead-canada\/pdfs\/product-monographs\/tecartus_english_pm.pdf."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: Results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1182\/blood.2024024667","article-title":"Sustained benefit of zanubrutinib vs ibrutinib in patients with R\/R CLL\/SLL: Final comparative analysis of ALPINE","volume":"144","author":"Brown","year":"2024","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1200\/JCO.22.02830","article-title":"Zanubrutinib versus ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: Final analysis from the randomized phase III ASPEN study","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_55","unstructured":"Canada\u2019s Drug Agency (2026, January 06). Acalabrutinib Reimbursement Review. Available online: https:\/\/www.cda-amc.ca\/acalabrutinib."},{"key":"ref_56","unstructured":"Cancer Care Ontario (2026, January 07). Drug Formulary: Cytarabine. Last Updated: July 2025. Available online: https:\/\/www.cancercareontario.ca\/en\/drugformulary\/drugs\/monograph\/43901."},{"key":"ref_57","unstructured":"Pharmascience (2026, January 07). Product Monograph: CYTOSAR (Cytarabine for Injection). Date of Revision. Available online: https:\/\/pdf.hres.ca\/dpd_pm\/00039384.PDF."},{"key":"ref_58","first-page":"92","article-title":"Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: Results of the phase I\/II BRUIN trial","volume":"110","author":"Shah","year":"2025","journal-title":"Haematologica"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.23.02470","article-title":"Glofitamab in relapsed\/refractory mantle cell lymphoma: Results from a phase I\/II study","volume":"43","author":"Phillips","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1182\/blood-2024-200770","article-title":"Trial in progress: Odronextamab for the treatment of patients with relapsed\/refractory mantle cell lymphoma following prior BTK inhibitor therapy\u2014A cohort of the ELM-2 study","volume":"144","author":"Cho","year":"2024","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1182\/bloodadvances.2020002068","article-title":"Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma","volume":"4","author":"Villa","year":"2020","journal-title":"Blood Adv."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1080\/10428194.2023.2226278","article-title":"Estimating the impact of early bendamustine failure on feasibility of subsequent CAR-T cell therapy in mantle cell lymphoma","volume":"64","author":"Puckrin","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.22.01797","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: Results from the US Lymphoma CAR T Consortium","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41408-025-01225-9","article-title":"Risk factors for CAR T-cell manufacturing failure and patient outcomes in large B-cell lymphoma: A report from the UK National CAR T Panel","volume":"15","author":"Dulobdas","year":"2025","journal-title":"Blood Cancer J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: The BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1182\/blood-2023-182942","article-title":"Multicenter study of mantle cell lymphoma outcomes following first-line bendamustine-rituximab and second-line Bruton\u2019s tyrosine kinase inhibitor therapy","volume":"142","author":"Wang","year":"2023","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.2021014162","article-title":"Zanubrutinib in relapsed\/refractory mantle cell lymphoma: Long-term efficacy and safety results from a phase 2 study","volume":"139","author":"Song","year":"2022","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e928","DOI":"10.1097\/HS9.0000000000000928","article-title":"Nationwide assessment of patient trajectories in mantle cell lymphoma: The Swedish MCLcomplete Project","volume":"7","author":"Jerkeman","year":"2023","journal-title":"HemaSphere"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/bjh.19179","article-title":"Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care and outcomes in a series from Australia and the United Kingdom","volume":"204","author":"Minson","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e609_70096","DOI":"10.1002\/hon.70096_609","article-title":"609|Real-world treatment patterns, clinical outcomes, and burden of illness of autologous stem-cell transplant ineligible patients with mantle cell lymphoma in Ontario, Canada","volume":"43","author":"George","year":"2025","journal-title":"Hematol. Oncol."},{"key":"ref_74","unstructured":"AstraZeneca Canada (2025). CALQUENCE (Acalabrutinib) Product Monograph, AstraZeneca Canada Inc.. Available online: https:\/\/www.astrazeneca.ca\/content\/dam\/az-ca\/downloads\/productinformation\/calquence-product-monograph-en.pdf."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood.2020008727","article-title":"Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: A phase 1\/2 trial","volume":"137","author":"Morschhauser","year":"2021","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"7044","DOI":"10.1200\/JCO.2025.43.16_suppl.7044","article-title":"Ibrutinib, venetoclax plus CD20 monoclonal Ab: Initial results of OASIS II, a prospective randomized phase 2 trial in previously untreated mantle cell lymphoma patients","volume":"43","author":"Eyre","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1182\/blood-2024-206778","article-title":"5-y follow-up of combination of ibrutinib, obinutuzumab and venetoclax for patients with newly diagnosed mantle cell lymphoma, the OAsIs trial","volume":"144","author":"Tessoulin","year":"2024","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"102060","DOI":"10.1016\/j.eclinm.2023.102060","article-title":"Trends in risk for therapy-related myelodysplastic syndrome\/acute myeloid leukemia after initial chemo\/immunotherapy for common and rare lymphoid neoplasms, 2000\u20132018","volume":"61","author":"Morton","year":"2023","journal-title":"eClinicalMedicine"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Phillips, T. (2025). Bending the needle: Phase III MANGROVE study in first-line mantle cell lymphoma. Hematologist, 22.","DOI":"10.1182\/hem.V22.5.2025512"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1038\/s41375-023-01977-y","article-title":"Clinical outcome of mantle cell lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression)","volume":"37","author":"Scheubeck","year":"2023","journal-title":"Leukemia"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1080\/10428194.2024.2373323","article-title":"Importance of long-term follow-up of autologous stem cell transplantation for mantle cell lymphoma","volume":"65","author":"Stewart","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1200\/JCO.23.01586","article-title":"Long-term follow-up of rituximab maintenance in young patients with mantle-cell lymphoma included in the LYMA trial: A LYSA study","volume":"42","author":"Sarkozy","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/hematology.2024000546","article-title":"To consolidate or not to consolidate: The role of autologous stem cell transplantation in MCL","volume":"2024","author":"Silkenstedt","year":"2024","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Hill, B.T. (2025). The end of transplant for mantle cell lymphoma. Hematologist, 22.","DOI":"10.1182\/hem.V22.1.202526"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/S0140-6736(24)00301-5","article-title":"Does TRIANGLE take down transplantation in mantle cell lymphoma?","volume":"403","author":"Martin","year":"2024","journal-title":"Lancet"},{"key":"ref_86","unstructured":"Hematology Advisor (2026, January 29). Ibrutinib Regimens \u201cPreferred\u201d, ASCT \u201cOut\u201d for Previously Untreated MCL. Available online: https:\/\/www.hematologyadvisor.com\/reports\/ibrutinib-regimens-preferred-asct-out-for-previously-untreated-mcl\/."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"LBA-6","DOI":"10.1182\/blood-2024-212973","article-title":"Lack of benefit of autologous hematopoietic cell transplantation (auto-HCT) in mantle cell lymphoma (MCL) patients (pts) in first complete remission (CR) with undetectable minimal residual disease (uMRD): Initial report from the ECOG-ACRIN EA4151 phase 3 randomized trial","volume":"144","author":"Fenske","year":"2024","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1080\/10428194.2023.2241095","article-title":"Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53-mutated disease","volume":"64","author":"Lew","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41419-020-03144-y","article-title":"Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance","volume":"11","author":"Kapoor","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/bjh.13149","article-title":"Combination of ibrutinib with ABT-199: Synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways","volume":"168","author":"Zhao","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(24)00682-X","article-title":"Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): A multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"26","author":"Wang","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2025-888","article-title":"Preliminary safety and efficacy of BOven (zanubrutinib, obinutuzumab, and venetoclax) as frontline therapy for older patients with mantle cell lymphoma","volume":"146","author":"Kumar","year":"2025","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/hon.3163_101","article-title":"Ibrutinib-rituximab and venetoclax (IRV) followed by risk-stratified R-hyper-CVAD\/MTX in young patients with untreated mantle cell lymphoma\u2014Phase-II WINDOW-2 trial","volume":"41","author":"Wang","year":"2023","journal-title":"Hematol. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/7\/426\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T04:18:17Z","timestamp":1784434697000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/7\/426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":93,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["curroncol33070426"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33070426","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]}}}